Quantcast
Home > Quotes > MDCO
MDCO

Medicines Company (The) Common Stock (MDCO) Quote & Summary Data

$20.79
*  
0.35
1.71%
Get MDCO Alerts
*Delayed - data as of Nov. 21, 2018 10:49 ET  -  Find a broker to begin trading MDCO now
Exchange:NASDAQ
Industry: Health Care
Community Rating:
View:    MDCO Real Time
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

Best Bid / Ask
$ 20.74 / $ 20.79
1 Year Target
47
Today's High / Low
$ 21.13 / $ 20.53
Share Volume
130,409
50 Day Avg. Daily Volume
1,068,271
Previous Close
$ 20.44
52 Week High / Low
$ 41.57 / $ 19.55
Market Cap
1,535,594,639
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -3.55
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.07

Intraday Chart

Shares Traded

Share Volume:
130,409
50 Day Avg. Daily Volume:
1,068,271

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -3.55

Trading Range

The current last sale of $20.79 is 6.34% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 21.13 $ 41.57
 Low: $ 20.53 $ 19.55

Company Description (as filed with the SEC)

We are a biopharmaceutical company driven by an overriding purpose - to save lives, alleviate suffering and contribute to the economics of healthcare. Our goal is to create transformational solutions to address the most pressing healthcare needs facing patients, physicians and providers in cardiovascular care. We are focused on inclisiran, an investigational agent which is potentially a first-in-class lipid-lowering drug, to reduce LDL-cholesterol, or LDL-C, which is commonly referred to as "bad" cholesterol, in patients with atherosclerotic cardiovascular disease, or ASCVD, or cardiovascular risk-equivalents. We believe that inclisiran possesses favorable attributes that competitive products do not possess, would satisfy unmet medical needs and has the potential to improve the economics of healthcare. We have the right to develop, manufacture and commercialize inclisiran under our collaboration agreement with Alnylam Pharmaceuticals, Inc., or Alnylam.  ... More ...  


Risk Grade

Where does MDCO fit in the risk graph?


Risk Grade Scale

Nasdaq Official Price

Open Price:
$ 20.53
Open Date:
Nov. 21, 2018
Close Price:
N/A
Close Date:
N/A

Consensus Recommendation

Analyst Info



Another Bailout?? Why is the SEC boosting big banks and HFT's bottom lines?
x